Emmaus Life Sciences has announced the use of its pharmaceutical-grade L-glutamine (PGLG) in a clinical study to determine its efficacy in lowering blood sugar in patients with type II diabetes.
The open-label pilot study is being conducted by Charles R. Zerez, Ph.D., M.D. and his co-investigator, Frank Singer, M.D., of Straub Medical Center in Honolulu, Hawaii. The first patient has been dosed and it is anticipated that total enrollment will include 20 to 30 female and male patients ages 18 and older who have been diagnosed with diabetes mellitus type II.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox! Sign up now!
"We are excited to collaborate with the Straub Medical Center to begin to better understand the role of PGLG in the treatment of diabetes," said Yutaka Niihara, M.D., M.P.H., Chairman and Chief Executive Officer of Emmaus. "Diabetes has been among the targets for Emmaus as we look to expand the therapeutic application of PGLG."
"Type II diabetes is the most common form of the disease and having evidence that PGLG could lower blood sugar would have significant implications for patients in search of a safe and effective treatment," said Dr. Zerez, Internal Medicine. "I look forward to studying the efficacy of PGLG, which hopefully leads to a new treatment that improves the lives of patients with diabetes."